Transforming Emergency Medical Care with CARL® ECPR System
FRIEBURG, Germany – Resuscitec GmbH has unveiled a groundbreaking medical technology poised to redefine emergency care. Their remarkable CARL® ECPR system, a highly efficient Extracorporeal Cardiopulmonary Resuscitation platform, has received nomination for the esteemed Prix Galien USA 2025 Award—an accolade often described as the "Nobel Prize of biopharmaceutical innovation." This nomination highlights the potential of this revolutionary technology in reshaping the future of health care.
A New Era in Cardiac Arrest Survival Rates
The implementation of Resuscitec's CARL® system marks a significant milestone in cardiac arrest management. The technology takes charge of heart and lung functions during sudden cardiac arrest, successfully supporting extracorporeal blood circulation and gas exchange until the patient's cardiovascular function is restored. Impressively, the CE marked system has been effectively utilized in over 750 clinical instances across Europe. In cases of cardiac arrest, survival rates have remarkably exceeded 50%, while 80% of survivors have shown no brain damage, significantly greater than the less than 10% survival typically seen with conventional CPR methods, including chest compressions and defibrillation.
Current Deployment Across Europe
Currently operational in 12 European countries and select locations in the Gulf Cooperation Council (GCC), the CARL® system is making waves in emergency rooms, cardiac care units, ambulances, and rescue helicopters. Resuscitec is actively pursuing FDA approval to extend the reach and impact of this life-saving technology.
Leading-Edge Innovation in Resuscitation
CARL® integrates physiologically guided ECPR, representing a notable advancement in resuscitation practices. By rerouting blood through an external circuit, it preserves life and organ viability during critical windows where traditional methods may falter. An interdisciplinary team spearheaded by Prof. Dr. Georg Trummer and Prof. Dr. Christoph Benk has been pivotal in developing this promising technology, merging expert knowledge from emergency medicine and medical engineering.
Future Enhancements Under Development
Dr. Tom Lines, the Chief Scientific Officer at Resuscitec, is at the forefront of ongoing development efforts, concentrating on incorporating lysis and plasma expansion technologies aimed at further maximizing survival rates.
Broader Applications and Collaborations
Beyond emergency medicine, Resuscitec is engaging in promising collaborations, notably with Walter Reed National Military Medical Center, to tailor the CARL® ECPR system for applications in military settings, focusing on resuscitation and organ preservation in contexts of massive blood loss. Future possibilities also include explorations in space medicine, oncology, and enhancing organ preservation protocols for transplantation.
Recognition and Impact of Prix Galien USA 2025 Nomination
The nomination for the CARL® system in the "Best Startup" category at the Prix Galien USA 2025 Awards highlights its transformative potential in global health care. The ceremony is set to occur at the American Museum of Natural History, celebrating innovations that significantly enhance human health.
"At Resuscitec, our mission is clear: we strive to offer individuals a second chance at life, even after facing a clinical death. This pursuit is both a privilege and an immense responsibility for our team," stated Prof. Trummer.
About Resuscitec
Resuscitec GmbH is dedicated to innovating advanced technologies aimed at resuscitation, organ preservation, and circulatory support, pushing the limits of life-saving medical care.
Media Contact Information
For more information, please contact Angela Gorman at AMWPR. Reach her at angela@amwpr.com.
Frequently Asked Questions
What is the CARL® ECPR system?
The CARL® ECPR system is an advanced technology that takes over heart and lung functions during cardiac arrest to maintain blood circulation and gas exchange.
What are the survival rates associated with the CARL® system?
Survival rates using the CARL® system have exceeded 50% in clinical cases, with 80% of survivors experiencing no brain damage.
In which countries is the CARL® system currently deployed?
The CARL® ECPR system is operational in 12 European countries and some Gulf Cooperation Council countries.
What future applications are being explored for the CARL® system?
Potential future applications include military settings, space medicine, oncology, and transplant organ preservation.
Who leads the development of the CARL® system?
The development is under the guidance of Dr. Tom Lines, along with contributions from Prof. Dr. Georg Trummer and Prof. Dr. Christoph Benk.
